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Abstract: Heterocycles bearing a hydrazine moiety react with 
bisaldehydes or bisketones to afford new Nx polydentate ligands 
suitable for α-radioimmunotherapy. We developed a fast and 
efficient method using microwave-assisted technology to obtain 
chelators with variable size and number of coordination centres 
which were fully characterized. The complexation efficiency with 
astatine will be assessed. 
Key words: Astatine, radioimmunotherapy, pyrimidinone, triazi-
none, chelating agent. 
Radioimmunotherapy (RIT) is a developing and promis-
ing technique for the treatment of small tumors.
1-3
 It 
consists of injecting patients with a radiopharmaceutical 
able to target and selectively destroy tumour cells. The 
radionuclides usually used are ? or ?- emitters with a 
short half-life, attached to a vector (antibody or hapten) 
through a bifunctional chelating agent.
4-6
 In order to 
minimize irradiation of healthy tissue whilst delivering 
radionuclides to tumors, the metal complex between 
chelating agent and radionuclide has to be stable in hu-
man serum.  
Among the potential radionuclides, 
211
At has attracted 
interest as a prospective candidate for α-
radioimmunotherapy applications due to its adequate 
physicochemical characteristics: α-emitter with a half-
life of 7.2 h, the emission of high energy α particles (6.8 
MeV), and ability to deposit large amounts of energy in a 
microvolume.
7
 Astatine is also an x-ray emitter allowing 
external imaging of the radiopharmaceutical distribution. 
Nevertheless, the chemistry of astatine remains in its 
infancy due to the absence of a stable isotope. The cur-
rent approach for labelling biomolecules with 
211
At rests 
on covalent attachment to a carbon atom.
8
 Unfortunately, 
a significant number of studies have shown that astati-
nated radiopharmaceuticals can be stable to in vitro con-
ditions, but generally more unstable in vivo.
9,11
 Neverthe-
less, clinical studies are in progress in United State and 
in Sweden.
12,13
 Although it is clear that much of the 
chemistry ascribed to halogens is applicable, the chemi-
cal similarity between astatine and its nearest halogen 
neighbour, iodine, is not always obvious. The general 
trend in the periodic system suggests that astatine is 
more metallic in character than iodine. Indeed, it has 
been reported that astatine presents a metal-like behav-
iour when existing under the oxidation states +I and +III 
as At
+
 and AtO
+
 species.
14,15
 Different groups have re-
ported the formation of coordination complexes between 
AtO
+
 and N
-
 or S
-
 containing organic chelating agents.
16-
18
 The stability of these complexes is however not suffi-
cient to use this chelation approach in RIT.  
These considerations brought us to develop new Nx 
polydentate ligands with variable size and number of 
coordination centres. At the same time as a fundamental, 
theoretical and pragmatic study around element astatine, 
we led here a purely empirical approach. This paper 
reports the synthesis of chelating agents L1-8 containing 
heterocyclic rings (Figure 1). Our expertise in the syn-
thesis of heterocycles led us to this choice of ligands. 
They present a semi-rigid scaffold due to partial conju-
gation between the linker and heterocycle. This charac-
teristic is essential to preorganization, an important 
ligand property.
19,20
 The degree of freedom is minimized, 
so that the structure of the chelate before complexation is 
similar to that in the complex. Preorganization provides 
high thermodynamic stability as well as increased kinetic 
inertness of the metal complex. 
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Figure 1 Polydentate chelators prepared in the study 
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Commercially available methylisothiocyanate was used 
as the starting reagent for the synthesis of chelating 
agents L1-8. The key step in this synthetic process was 
the preparation of the two corresponding hydrazino-
heterocyclic rings 3 and 4 (Scheme 1). The intermediary 
pyrimidinone 1 and triazinone 2 were obtained in high 
yields according to our previously described methodol-
ogy.
21,22
 Nucleophilic displacement of the methylsulfanyl 
group of 1 and 2 with hydrazine was carried out using 
ethanol as solvent to afford 2-hydrazonopyrimidine 3 
and 2-hydrazonotriazine 4.
23
 The reaction was performed 
under microwave irradiation in order to minimize reac-
tion time and secondary reactions. Indeed, with 
pyrimidinone 1, at room temperature and after 20 h, a 
by-product (20%) resulting from double attack of hydra-
zine onto two heterocycles, was observed.  
 
Scheme 1 Synthetic route to heterocyles 3 and 4 
Finally, the heterocyclic rings 3 and 4 were converted to 
the new polydentate ligands L1-8 with 4 to 6 coordination 
centres (N4, N5 and N6) by a double imination reaction 
with dialdehydes 5,8 or diketones 6,7.
24
 These carbonyl 
compounds were commercially available except 5. This 
latter compound was prepared by initial reduction (using 
BH3.THF) of 5-tert-butylisophtalic acid to give the cor-
responding diol, which was subsequently oxidized 
(PCC/CH2Cl2) into the dialdehyde.
25
 
To prepare N4 tetradentate ligands L1-4, two equivalents 
of heterocyclic ring 3 or 4 were reacted with 1,3-
bis(formyl)-5-tert-butylbenzene 5 or butane-2,3-dione 6 
(Scheme 2). The syntheses were performed under mi-
crowave irradiation at 110°C in ethanol for dialdehyde 5 
and at 130°C in acetic acid for diketone 6 and afforded 
the N4 ligands in high yields.
24
 Microwave irradiation 
significantly improved yields and condensation reaction 
kinetics compared to conventional thermal protocol.  
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Scheme 2 Tetradentate ligands L1-4 with pyrimidinone and triazinone scaffolds.
N5 pentadentate ligands were prepared in a similar way. 
Reaction of heterocyclic ring 3 or 4 with diace-
tylpyrimidine 7 led to the formation of ligands L5 and L6 
(scheme 3). The reaction proceeded at 130°C in acetic 
acid under microwave irradiation affording the ligands in 
high yields. 
 
Scheme 3 Pentadentate ligands L5 and L6 with pyrimidinone and triazinone scaffolds
Finally, N6 hexadentate ligands L7 and L8 were analo-
gously prepared by condensation of 2,9-
diformylphenanthroline 8 and pyrimidine 3 or triazine 4 
(Scheme 4). These N6 ligands posses the rigidity im-
posed by the central phenantroline ring and the flexibil-
ity of the heterocyclic arms.  
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Scheme 4 Hexadentate ligands L7 and L8 with pyrimidinone and triazinone scaffolds
All new ligands L1-8 were isolated with a high degree of 
purity by simple filtration after microwave heating in 
glass vial. Their structure was determined unequivocally 
by complementary 
1
H/
13
C-2D NMR techniques (COSY, 
HMQC and HMBC).
26
 
In conclusion, the synthesis of Nx polydentate ligands 
(N4, N5 and N6) was efficiently and simply performed by 
use of microwave-assisted technology. These chelators 
were prepared in 50-80% overall yield from methyli-
sothiocyanate. The described way of synthesis will be 
easily adaptable to various starting heterocyclic struc-
tures. Study of the complexing ability of these new che-
lating agents toward astatine, suitable for α-
radioimmunotherapy, is under progress. According to the 
results of this study we envision the synthesis of various 
analogues of ligands L1-8 in order to adjust their structure 
(size, nature, number of coordination centers and hetero-
cyclic ring) to finally find out the ligand which would be 
best suited for astatine. 
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